<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406104</url>
  </required_header>
  <id_info>
    <org_study_id>GS-LHON-CLIN-06</org_study_id>
    <secondary_id>2017-002153-11</secondary_id>
    <nct_id>NCT03406104</nct_id>
  </id_info>
  <brief_title>RESCUE and REVERSE Long-term Follow-up</brief_title>
  <acronym>RESCUE/REVERSE</acronym>
  <official_title>Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenSight Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenSight Biologics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to assess the long-term safety and efficacy of GS010, a
      gene therapy, and assess the quality of life in subjects with LHON due to the G11778A ND4
      mitochondrial mutation and who were treated in the Rescue or Reverse studies.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>intra patient comparaison</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs) or serious adverse events (SAEs) (ocular or systemic)</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>AEs or SAEs (ocular or systemic) related to IMP or administration procedure, as judged by the Investigator, reported during the long-term follow-up visits (2, 2.5, 3, 4, and 5 years) from the period of 96 weeks up to 5 years post-treatment and summarized descriptively by type, frequency (number, percentage), severity, causal relationship, and seriousness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-Corrected Visual Acuity (BCVA) reported with LogMAR</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Change in best BCVA reported with LogMAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HumphreyTM visual field (HVF) 30-2 parameters</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Change of parameters measured with HVF 30-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectral domain optical coherence tomography (SD-OCT) parameters</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Change of parameters measured with SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Response status of eyes treated with GS010 IVT injection compared to eyes treated with sham IVT injection (An improvement of at least 15 ETDRS letters/Eyes that lose less than the 15 ETDRS letters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of the response</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Time course of the response in eyes treated with GS010 IVT injection compared to eyes treated with sham IVT injection, for the BCVA reported with LogMAR, for parameters measured with HVF 30-2 and SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual improvement</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Visual improvement as measured by LogMAR by analysis of covariance (ANCOVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ganglion cell layer (GCL) thickness/volume and topographical map and other parameters measured by SD-OCT</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Change of GCL thickness/volume and topographical map and other parameters measured by SD-OCT using a mixed model of ANCOVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: Visual Functioning Questionnaire 25 (VFQ-25)</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>QOL as measured with VFQ-25 subject-rated instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: 36-Item Short Form Health Survey, version 2 (SF-36-v2)</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>QOL as measured with SF-36v2 subject-rated instrument</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Leber Hereditary Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>GS010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenadogene nolparvovec Intravitreal occular unilateral Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Intravitreal occular unilateral Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>GS010</intervention_name>
    <description>Lenadogene nolparvovec Intravitreal occular unilateral Injection</description>
    <arm_group_label>GS010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Lenadogene nolparvovec Intravitreal occular unilateral Injection</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subject was treated with GS010 IVT injection in either of the RESCUE or REVERSE Phase
             III clinical studies

          -  Subject of legal consent age has provided informed consent; subjects that are not of
             legal consent age have undergone their country-approved clinical trial enrollment
             consent process

        Non-Inclusion Criteria

          -  Subject is unwilling or unable to comply with the protocol requirements

          -  Subject has any medical or psychological condition that, in the opinion of the
             Investigator, may compromise his or her safe participation in the study

          -  Subject is taking or intending to take idebenone during the long-term follow-up study
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Newman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospital Atlanta, Georgia, United States, 30322</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Doheny Eye Center UCLA</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHNO Les Quinze Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München / Friedrich-Baur-Institut</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heredity Optic Atrophy</keyword>
  <keyword>Leber Hereditary Optic Atrophy</keyword>
  <keyword>Leber Hereditary Optic Neuropathy</keyword>
  <keyword>LHON</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Hereditary Eye Diseases</keyword>
  <keyword>Inborn Genetic Disease</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Intravitreal Injections</keyword>
  <keyword>Mitochondrial Disease</keyword>
  <keyword>AAV2 Vectors</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Neurodegenerative Disease</keyword>
  <keyword>Heredodegenerative Disorders of the Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

